Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Measuring Oncological Value of Exercise and Atorvastatin
2019-001982-34Phase 2Active
- Sponsor
- Pirkanmaan hyvinvointialue
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atorvastatin in breast cancer, Malignant ovarian neoplasm (OC), kidney cancer and 1 more (3 arms), sponsored by Pirkanmaan hyvinvointialue. Primary endpoint: Cancer progression or death. Started Mar 2022; status: active.
02
Drugs
atorvastatin
03
Conditions
breast cancerMalignant ovarian neoplasm (OC)kidney cancerprostate cancer (PCa)
Beyond the preview
Go deeper on 2019-001982-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001982-34.